Original Investigation
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
Naiyer A. Rizvi, MD; Byoung Chul Cho, MD, PhD; Niels Reinmuth, MD, PhD; Ki Hyeong Lee, MD, PhD; Alexander Luft, MD; Myung-Ju Ahn, MD; Michel M. van den Heuvel, MD, PhD; Manuel Cobo, MD, PhD; David Vicente, MD; Alexey Smolin, MD; Vladimir Moiseyenko, MD, PhD; Scott J. Antonia, MD, PhD; Sylvestre Le Moulec, MD; Gilles Robinet, MD; Ronald Natale, MD; Jeffrey Schneider, MD; Frances A. Shepherd, MD; Sarayut Lucien Geater, MD; Edward B. Garon, MD; Edward S. Kim, MD; Sarah B. Goldberg, MD; Kazuhiko Nakagawa, MD, PhD; Rajiv Raja, PhD; Brandon W. Higgs, PhD; Anne-Marie Boothman, DPhil; Luping Zhao, PhD; Urban Scheuring, MD, PhD; Paul K. Stockman, MBChB, PhD; Vikram K. Chand, MBBS; Solange Peters, MD, PhD; for the MYSTIC Investigators